Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing, China.
Laboratory of Cardiovascular Bioactive Molecule, School of Basic Medical Sciences, Peking University, Beijing, China.
Front Endocrinol (Lausanne). 2021 May 19;12:583575. doi: 10.3389/fendo.2021.583575. eCollection 2021.
We aimed to explore the role and possible mechanism of leptin in lower-extremity artery calcification in patients with type 2 diabetes mellitus (T2DM).
We recruited 59 male patients with T2DM and 39 non-diabetic male participants. All participants underwent computed tomography scan of lower-extremity arteries. The calcification scores (CSs) were analyzed by standardized software. Plasma leptin level was determined by radioimmunoassay kits. Human vascular smooth muscle cells (VSMCs) calcification model was established by beta-glycerophosphate and calcium chlorideinduction. Calcium deposition and mineralization were measured by the o-cresolphthalein complexone method and Alizarin Red staining. The mRNA expression of bone morphogenic protein 2 (BMP2), runt-related transcription factor 2 (Runx2), osteocalcin (OCN) and osteopontin (OPN) was determined by quantitative RT-PCR. The protein levels of BMP2, Runx2, α-smooth muscle actin (α-SMA) and (p)-Akt was determined by Western-blot analysis, and α-SMA was also measured by immunofluorescence analysis.
Compared with controls, patients with T2DM showed higher median calcification score in lower-extremity artery [286.50 (IQR 83.41, 1082.00) 68.66 (3.41, 141.30), <0.01]. Plasma leptin level was higher in patients with calcification score ≥300 than ≥100 (252.67 ± 98.57 189.38 ± 44.19 pg/ml, <0.05). Compared with calcification medium, intracellular calcium content was significantly increased in VSMCs treated by leptin (200, 400 and 800 ng/ml) combined with calcification medium [11.99 ± 3.63, 15.18 ± 4.55, and 24.14 ± 5.85 mg/ml, respectively, 7.27 ± 1.54 mg/ml, all <0.01]. Compared with calcification medium, Alizarin Red staining showed calcium disposition was more obvious, and the mRNA level of BMP2, Runx2 and OCN was significantly increased, and immunofluorescence and Western blot analysis showed that the expression of α-SMA was downregulated in VSMCs treated by leptin (400 ng/ml) combined with calcification medium, respectively. Compared with calcification medium, the protein level of BMP2 and Runx2 was upregulated in VSMCs treated by leptin (400 ng/ml) combined with calcification medium. Moreover, blocking PI3K/Akt signaling pathway can decrease the protein expression of BMP2 and Runx2 in VSMCs treated by leptin (400 ng/ml) combined with calcification medium.
Leptin promoted lower-extremity artery calcification of T2DM by upregulating the expression of BMP2 and Runx2, and regulating phenotypic switch of VSMCs PI3K/Akt signaling pathway.
探讨瘦素在 2 型糖尿病(T2DM)患者下肢动脉钙化中的作用及可能机制。
纳入 59 例男性 T2DM 患者和 39 例非糖尿病男性参与者。所有参与者均接受下肢动脉计算机断层扫描。采用标准化软件分析钙化评分(CSs)。采用放射免疫试剂盒测定血浆瘦素水平。采用β-甘油磷酸钠和氯化钙诱导人血管平滑肌细胞(VSMCs)钙化模型。茜素红染色法和邻甲酚酞络合酮法分别测定钙沉积和矿化程度。采用定量 RT-PCR 检测骨形态发生蛋白 2(BMP2)、 runt 相关转录因子 2(Runx2)、骨钙素(OCN)和骨桥蛋白(OPN)的 mRNA 表达。采用 Western blot 分析测定 BMP2、Runx2、α-平滑肌肌动蛋白(α-SMA)和(p)-Akt 的蛋白水平,并通过免疫荧光分析测定 α-SMA。
与对照组相比,T2DM 患者下肢动脉 CS 中位数较高[286.50(IQR 83.41,1082.00) 68.66(3.41,141.30),<0.01]。钙化评分≥300 的患者的血浆瘦素水平高于钙化评分≥100 的患者[252.67±98.57 189.38±44.19 pg/ml,<0.05]。与钙化培养基相比,瘦素(200、400 和 800 ng/ml)联合钙化培养基处理的 VSMCs 内钙含量显著增加[11.99±3.63、15.18±4.55 和 24.14±5.85 mg/ml,分别为 7.27±1.54 mg/ml,均<0.01]。与钙化培养基相比,茜素红染色显示钙沉积更为明显,BMP2、Runx2 和 OCN 的 mRNA 水平显著升高,瘦素(400 ng/ml)联合钙化培养基处理的 VSMCs 免疫荧光和 Western blot 分析显示α-SMA 的表达下调。与钙化培养基相比,瘦素(400 ng/ml)联合钙化培养基处理的 VSMCs 中 BMP2 和 Runx2 的蛋白水平上调。此外,PI3K/Akt 信号通路阻断可降低瘦素(400 ng/ml)联合钙化培养基处理的 VSMCs 中 BMP2 和 Runx2 的蛋白表达。
瘦素通过上调 BMP2 和 Runx2 的表达,调节 PI3K/Akt 信号通路,促进 T2DM 患者下肢动脉钙化,调节 VSMCs 的表型转换。